Hatteras Discovery

Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

Wildflower Health is building a mobile health engagement platform to improve healthcare quality and lower medical costs. Our team is passionate about harnessing user-centered design and technology to deliver products that drive smarter healthcare decisions. Over time, we aspire to leverage a unique set of analytics to deliver novel insights that improve treatment and cost-management in the clinical areas we support. We believe that innovative digital health solutions have the power to truly change healthcare.

SpineAlign Medical, Inc., a medical device company, develops and distributes medical devices and products to treat disorders of the spine. It offers VerteLift, a nitinol implant that is used in the treatment of vertebral compression fractures (occurs in patients suffering from osteoporosis) in the thoracic/lumbar spine. The company distributes its products in Europe. SpineAlign Medical, Inc. was formerly known as SpineWorks Medical, Inc. and changed its name to SpineAlign Medical, Inc. in May 2009. The company was founded in 2005 and is based in San Jose, California.

Boragen develops synthetic chemistry platforms designed to produce next-generation fungicides. The platform supports sustainable farming methods by creating a compound that decreases the probability of fungicide resistance and reduces the amount of chemical applied while maintaining performance and efficacy. The company utilizes boron’s unique properties to design and develop novel solutions targeting needs in crop protection, animal health, and human health. Founded in 2015, Boragen is based in Durham, North Carolina.

GeneCentric Diagnostics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

Medfusion is a provider of patient-to-provider communication solutions that enable healthcare providers to offer service to their patients while improving office efficiency and generating revenue. Originally established in Raleigh, North Carolina in 1996, Medfusion began providing medical website development and support to healthcare clients such as hospitals, physician groups, and insurance companies. In working with healthcare entities, Medfusion developed healthcare-specific functionality such as physician directories, eligibility software, and interactive survey-taking applications.

Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry

Boston Immune Technologies & Therapeutics, Inc., a biopharmaceutical company, develops immune-based approaches for the treatment of cancer and infectious diseases. The company develops immunotherapy for chronic infectious diseases. The company was incorporated in 2011 and is based in Winchester, Massachusetts.

ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.

GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and its own therapeutic products for major ocular disease indications including wet AMD and Glaucoma. The company was founded in 2011 and headquartered in Baltimore, Maryland.

Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.

ArtusLabs is developing and deploying Web 2.0 enabled software platforms that enable groups of scientists, and thereby individual scientists, to deliver significantly better (and more) business value to their shareholders, faster. ArtusLabs was founded by the same proven team that formed Synthematix, the award winning organization that pioneered the Enterprise Electronic Lab Notebook marketplace. This leadership and development team has extensive expertise in processing, mining and managing complex scientific data and information generated from research activities. With a wealth of experience and very close relationships with scientists around the globe, the team at ArtusLabs continues to build the best collaborative customer experience and technologies for researchers -- hands down.

Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.

NeuroTronik, spun out of medical technology incubator Synecor, is developing a medical device that could take the place of drugs currently used to heart failure. Read more about the company's technology,

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.

Elligo Health Research is revolutionizing the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health care informatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere.

Clinverse is a technology company solely focused on the financial management of clinical trials and associated payments in over 140 currencies. Our flagship product, ClinPay, is a secure on-line eClinical Trial Payment Network that dramatically reduces time spent on the investigator payment process with significant increases in clinical trial productivity. ClinPay links sponsors to investigators in a payment and reporting system that reduces study start-up time, makes possible timely and accurate payments, provides transparency and auditing records, and simplifies compliance.

Sideris Pharmaceuticals Inc. is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of transfusion-related iron overload. The company’s operations include facilities in Boston, MA, and in Gainesville, FL.

StrideBio, Inc. creates and develops adeno-associated viral (AAV) vector technologies and therapeutics that enables gene addition, gene silencing, and gene editing modalities for rare diseases. The company develops a proprietary platform by combining structural information with accelerated evolution to create novel AAV capsids that can evade neutralizing antibodies. The company was founded in 2015 and is based in Durham, North Carolina.

Contego Medical, Inc. develops emboli protection devices that are used for the treatment of cardiovascular and endovascular diseases. It offers angioplasty balloons and stent delivery catheters, such as coronary stent systems, carotid post-dilation balloons, and renal artery stent systems with integrated embolic protection devices for enabling carotid, renal, SVG, and coronary interventions. Contego Medical, Inc. was formerly known as Contego Medical, LLC. The company was founded in 2005 and is based in Raleigh, North Carolina with an additional office in Curitiba, Brazil.

Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.

Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.

Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

AtaCor Medical, Inc. develops pacemaker system that keeps the heart and veins free from pacing leads and hardware. It offers AtaCor EV Temporary Pacing System, an implantable temporary pacing system that uses a parasternal approach for implantable, extravascular temporary pacing. The company’s AtaCor EV Temporary Pacing System advances a custom pacing lead into the extracardiac tissue between the ribs and pericardium to restore cardiac rhythm for patients. AtaCor Medical, Inc. was incorporated in 2014 and is based in San Clemente, California.

Wildflower Health is building a mobile health engagement platform to improve healthcare quality and lower medical costs. Our team is passionate about harnessing user-centered design and technology to deliver products that drive smarter healthcare decisions. Over time, we aspire to leverage a unique set of analytics to deliver novel insights that improve treatment and cost-management in the clinical areas we support. We believe that innovative digital health solutions have the power to truly change healthcare.

Clinipace is a clinical research organization that specializes in fully integrated clinical research services for biopharmaceutical and medical device firms. It delivers a level of collaboration and flexibility not possible in a traditional CRO environment. The company was founded in 2003 and headquartered in Morrisville, North Carolina.

Standard Bariatrics is a medical device company that develops and offers surgical instruments for weight loss surgeries. The company offers Standard Clamp, an instrument that helps surgeons standardize their individual techniques to reduce variation, improve efficiency, and eliminate waste when performing a laparoscopic sleeve gastrectomy. Standard Bariatrics was founded in 2014 and is based in Cincinnati, Ohio.

GeneCentric Diagnostics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

Artizan Biosciences, Inc. develops small molecule drugs for use in humans. The company use IgA-SEQ technology platform to distinguish disease-driving bacteria from the intestinal microbiota to developing new and potentially curative treatments. Artizan Biosciences, Inc. was founded in 2016 and is headquartered in New Haven, Connecticut.

Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.

GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and its own therapeutic products for major ocular disease indications including wet AMD and Glaucoma. The company was founded in 2011 and headquartered in Baltimore, Maryland.

ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

Pathfinder Therapeutics

AN2 Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of novel medicines targeting infectious diseases. The company focuses on developing a clinical-stage antibacterial compound. It has a strategic partnership with Brii Biosciences. The company was incorporated in 2017 and is based in Menlo Park, California.

Elligo Health Research is revolutionizing the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health care informatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere.

CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.

Gobiquity, Inc. provides prescribed mobile health applications for the early detection and prevention of health disorders and chronic diseases. It offers GoCheck Kids, a smartphone app that detects amblyopia risk factors and meets the American Association for Pediatric Ophthalmology and Strabismus guidelines for vision screening in children. Gobiquity, Inc. was formerly known as ICHECK Health Connection, Inc. The company was founded in 2010 and is based in Aliso Viejo, California.

Healthcare is extremely inefficient due to complex and disparate systems that don’t talk to each other. The explosion of data further compounds the problem. Huma.AI improves (if not solves) this inefficiency by serving as the connective tissue between system silos allowing “mere mortals” to automatically access data, gain insights and take action using everyday language.

NoviSci improve the health and well-being of people through principled data science.

Jumo Health develops age-appropriate, educational resources for patients and caregivers for use throughout their medical journey. It works with providers, manufacturers, and advocacy groups, to ensure resources are available at the moment of diagnosis, during a treatment regimen, or while participating in a clinical trial. The company was founded in 2009 and is headquartered in New York, United States.

G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigational therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer.

Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry

Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

StrideBio, Inc. creates and develops adeno-associated viral (AAV) vector technologies and therapeutics that enables gene addition, gene silencing, and gene editing modalities for rare diseases. The company develops a proprietary platform by combining structural information with accelerated evolution to create novel AAV capsids that can evade neutralizing antibodies. The company was founded in 2015 and is based in Durham, North Carolina.

G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigational therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer.

Artizan Biosciences, Inc. develops small molecule drugs for use in humans. The company use IgA-SEQ technology platform to distinguish disease-driving bacteria from the intestinal microbiota to developing new and potentially curative treatments. Artizan Biosciences, Inc. was founded in 2016 and is headquartered in New Haven, Connecticut.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

Spyryx Biosciences, Inc., a biopharmaceutical company, develops inhaled peptide therapeutics for obstructive lung diseases. It focuses on cystic fibrosis and chronic obstructive pulmonary diseases. Spyryx Biosciences, Inc. was formerly known as Spyryx LLC. The company was incorporated in 2013 and is headquartered in Durham, North Carolina.

Bivarus, Inc. develops a cloud-based analytics platform for measuring continuous quality improvement (CQI) and the patient experience to hospital-based outpatient service lines, community-based clinics, and group practices through patient-centered insights. Its platform enables customers to gain insights into the drivers impacting the patient experience, buying behavior, and provider performance, as well as to improve patient care and service operations. Bivarus, Inc. was founded in 2010 and is based in Durham, North Carolina. As of January 16, 2018, Bivarus, Inc. operates as a subsidiary of Press Ganey Holdings, Inc.

Clinipace is a clinical research organization that specializes in fully integrated clinical research services for biopharmaceutical and medical device firms. It delivers a level of collaboration and flexibility not possible in a traditional CRO environment. The company was founded in 2003 and headquartered in Morrisville, North Carolina.

Bivarus, Inc. develops a cloud-based analytics platform for measuring continuous quality improvement (CQI) and the patient experience to hospital-based outpatient service lines, community-based clinics, and group practices through patient-centered insights. Its platform enables customers to gain insights into the drivers impacting the patient experience, buying behavior, and provider performance, as well as to improve patient care and service operations. Bivarus, Inc. was founded in 2010 and is based in Durham, North Carolina. As of January 16, 2018, Bivarus, Inc. operates as a subsidiary of Press Ganey Holdings, Inc.

Rodin Therapeutics, a biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, announced its founding by Atlas Venture and Proteros biostructures. Rodin is founded based on its insight into key epigenetic modulators of CNS function, privileged access to Proteros' best-in-class structural biology capabilities, and a team with deep CNS drug development and company formation experience. Rodin secured financing from Atlas Venture and Johnson & Johnson Development Corporation (JJDC).

Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.

Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Their strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.

Mati Inc. produces and sells energy drinks in various flavors. It offers MATI, an energy drink that is brewed from plants, fruit juice concentrates, water, and other products. The company sells its products through wholesalers, retail outlets, and wholesale food stores in North Carolina; and Durham, Orange, Person, Vance, Granville, Franklin, and Warren counties, as well as online. Mati Inc. was incorporated in 2012 and is based in Durham, North Carolina. As of April 27, 2020, Mati Inc. operates as a subsidiary of NOBL Beverages.

NuSirt Sciences, Inc. develops a technology platform that combines natural compounds with various pharmaceutical agents to prevent and treat chronic diseases resulting from over-nutrition and aging. Its technology platform focuses on activating sirtuin pathways through the administration of natural compounds in specific combinations at precise doses. The company develops a formula to reduce the amount of generic drug metformin needed for blood sugar control. It focuses on various disease areas, such as type 2 diabetes and pre-diabetes; and non-alcoholic fatty liver disease/non-alcoholic steatohepatosis. NuSirt Sciences, Inc. has a strategic partnership with One Way Liver S.L. NuSirt Sciences, Inc. was formerly known as Nutraceutical Discoveries, Inc. The company was founded in 2007 and is based in Nashville, Tennessee.

HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Curoverse, Inc. develops and operates a cloud based open source platform under the name Arvados for storing, organizing, analyzing, and sharing genomic data. Curoverse, Inc. was formerly known as Clinical Future, Inc. and changed its name to Curoverse, Inc. in December 2013. The company was incorporated in 2010 and is based in Boston, Massachusetts. As of August 3, 2017, Curoverse, Inc. operates as a subsidiary of Veritas Genetics International Ltd.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.

Elligo Health Research is revolutionizing the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health care informatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere.

Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.

Empliant, Inc., located in Chapel Hill, N.C., provides web-native, employee self-reliant data collection solutions. Online benefits enrollment reduces administrative costs, increases employee satisfaction, and enhances operational efficiency. Their technology applications include on-line benefits enrollment and administration and personalized employee benefits statements. They also deliver a fully searchable content management knowledgebase for benefit plan information, company policies, or management practices. Their Software as a Service (SaaS) solution eliminates up front costs and enables employers to provide employees with self-service capabilities for pennies a day per employee. Empliant offers small to medium-sized enterprises (SME) the rich functionality found in expensive applications without the consulting costs, long implementation period, and reliance on customer support and product maintenance.

Coferon is a biotechnology company that employs bioorthogonal linker chemistry to deliver therapeutic molecules in component parts that self assembles inside target cells. The Company is based at the Long Island High Tech Incubator on the campus of Stony Brook University in Stony Brook, New York.

Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.

Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

Altis Biosystems is a biotechnology company developing research tools for the pharma and biotech industries. The company has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. Their organ on a chip product produces a layer of human or animal intestinal stem and differentiated cells, either of the small or large intestine. These cells can be used for disease modeling, precision medicine, microbiome research, and compound screening.

Clinipace is a clinical research organization that specializes in fully integrated clinical research services for biopharmaceutical and medical device firms. It delivers a level of collaboration and flexibility not possible in a traditional CRO environment. The company was founded in 2003 and headquartered in Morrisville, North Carolina.

Clinipace is a clinical research organization that specializes in fully integrated clinical research services for biopharmaceutical and medical device firms. It delivers a level of collaboration and flexibility not possible in a traditional CRO environment. The company was founded in 2003 and headquartered in Morrisville, North Carolina.

410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously. This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited. It was founded in 2013 and headquartered in Durham, North Carolina.

Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Their strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies.

GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and its own therapeutic products for major ocular disease indications including wet AMD and Glaucoma. The company was founded in 2011 and headquartered in Baltimore, Maryland.

G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigational therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company’s lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.

Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.

Founded by nurses and technology entrepreneurs, NurseGrid makes integrated, intuitive staffing and communication tools just for nurses and nursing departments. NurseGrid has two products: NurseGrid Mobile & NurseGrid Manager. NurseGrid Mobile is the easiest way for nurses and healthcare workers to manage their complex schedules, connect with colleagues, and bring more balance to their work lives. More than 300,000 nurses have downloaded NurseGrid to date and the iOS app enjoys a consistent 5 star average rating on the App Store. NurseGrid Manager allows nursing departments to simplify team communication, staffing, and schedule management, making staff and managers happier and more productive. It complements core scheduling systems such as Kronos, API, and McKesson, filling in the critical gap current technologies leave between schedule creation and timekeeping, and giving nurse leaders a cost-saving, nurse-preferred way to manage day to day staffing and scheduling needs. NurseGrid was launched in 2013.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.

Qpex Biopharma develops a pipeline of agents addressing critical needs for the treatment of infectious diseases. It develops multiple antibiotic drugs intended to combat antimicrobial resistance. The company's technology is focused on targeting the treatment of infectious diseases for both inpatient and outpatient cases, deep expertise in the discovery, development and regulatory approval of anti-infective medicines, including an extensive record of working with public/private partnerships focused on new antibiotics to combat antimicrobial resistance, enabling medical businesses optimal use of products and critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. It was founded in 2018 and is headquartered in San Diego, California.

WalletFi offers a proprietary platform that identifies recurring charges, subscriptions, and CoF payments, and allows users and financial institutions to transfer those payments to a new card in case of re-issuance. WalletFi reduces customer churn for banks and financial institutions while also increasing customer engagement and reinforcing top-of-wallet status.

Wildflower Health is building a mobile health engagement platform to improve healthcare quality and lower medical costs. Our team is passionate about harnessing user-centered design and technology to deliver products that drive smarter healthcare decisions. Over time, we aspire to leverage a unique set of analytics to deliver novel insights that improve treatment and cost-management in the clinical areas we support. We believe that innovative digital health solutions have the power to truly change healthcare.

Standard Bariatrics is a medical device company that develops and offers surgical instruments for weight loss surgeries. The company offers Standard Clamp, an instrument that helps surgeons standardize their individual techniques to reduce variation, improve efficiency, and eliminate waste when performing a laparoscopic sleeve gastrectomy. Standard Bariatrics was founded in 2014 and is based in Cincinnati, Ohio.

Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.

ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

Artizan Biosciences, Inc. develops small molecule drugs for use in humans. The company use IgA-SEQ technology platform to distinguish disease-driving bacteria from the intestinal microbiota to developing new and potentially curative treatments. Artizan Biosciences, Inc. was founded in 2016 and is headquartered in New Haven, Connecticut.

StrideBio, Inc. creates and develops adeno-associated viral (AAV) vector technologies and therapeutics that enables gene addition, gene silencing, and gene editing modalities for rare diseases. The company develops a proprietary platform by combining structural information with accelerated evolution to create novel AAV capsids that can evade neutralizing antibodies. The company was founded in 2015 and is based in Durham, North Carolina.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.